Phibro(US:PAHC)2024-08-29 21:25Financial Performance - Q4 FY24 (Year-on-Year) - Consolidated net sales increased by 7% to $273.2 million[10] - Consolidated net income decreased significantly by 93% to $0.8 million[10] - Consolidated adjusted EBITDA increased by 3% to $33.4 million[10] - Animal Health sales increased by 8% to $191.5 million, with MFAs & other up 12%, vaccines up 14%, but nutritional specialties down 4%[15] Financial Performance - Full Year FY24 (Year-on-Year) - Consolidated net sales increased by 4% to $1,017.7 million[12] - Consolidated net income decreased significantly by 93% to $2.4 million[12] - Consolidated adjusted EBITDA decreased by 1% to $111.2 million[12] - Animal Health sales increased by 7% to $706.5 million, with vaccines up 21%, MFAs & other up 9%, but nutritional specialties down 5%[18] Acquisition and Guidance - The company is acquiring Zoetis' MFA and certain water-soluble products business for $350 million[7] - The company expects net sales of $1.040 billion to $1.090 billion and adjusted EBITDA of $118 million to $126 million for FY2025[7] Capitalization - Free cash flow was $46 million for the trailing twelve months[26] - Gross leverage ratio is 4.4x, with $489 million total debt / $111 million TTM adjusted EBITDA[26]